Agencies agree to purchase investigational antiviral if authorized by FDA
The departments of Health and Human Services and Defense will purchase 1.7 million treatment courses of an investigational antiviral drug for $1.2 billion if the Food and Drug Administration approves or authorizes the therapy, the Biden administration announced today.
If authorized, the federal government will allocate the drug (molnupiravir) to states and territories. Health care providers would order the drug directly from the distributor within those allocations, HHS said.
Related News Articles
Perspective
This week, more than 1,000 hospital and health system leaders came to Washington, D.C., united by a shared responsibility: to ensure every community has access…
Headline
The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to expedite access to certain FDA-…
Headline
The Senate April 23 adopted a budget resolution by a 50-48 vote, paving the way for a narrow reconciliation bill focused on immigration enforcement funding.…
Perspective
Two days from now, the AHA will welcome more than 1,000 health care leaders to our 2026 Annual Membership Meeting in Washington, D.C.This yearly gathering…
Headline
Secretary of Health and Human Services Robert F. Kennedy Jr. April 16 testified during two House hearings on the HHS fiscal year 2027 budget proposal, which…
Perspective
Just 23 days from now, more than 1,000 hospital and health system leaders from across the country will arrive in Washington, D.C., for the 2026 AHA Annual…